B of A Securities Maintains Buy on Vera Therapeutics, Raises Price Target to $70

Benzinga Newsdesk www.benzinga.com Positive 83.8%

Neg 0% Neu 0% Pos 83.8%

B of A Securities analyst Dina Ramadane maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $65 to $70.